Expert Interview
An in-depth examination of tradipitant, following Vanda’s release of its Motion Sickness results
Ticker(s): VNDAA neurologist with experience in Motion Sickness and knowledge of Vanda’s tradipitant.
Please tell us about your clinical experience. How many patients do you see with Motion Sickness, and what is your treatment of choice?
Added By: slingshot_insightsWhat is the mechanism of action of a neurokinin-1 receptor antagonist like tradipitant?
- What characteristics of it made Vanda pursue atopic dermatitis and gastroparesis indications as well?
Added By: slingshot_insights
In the recent data, 72.2% of the placebo treated patients experienced vomiting vs 15.8% of those treated with tradipitant under "rough" conditions. However, the specific conditions and how they are controlled are unclear; is there any standardisation for this type of motion sickness trials?
- What is your interpretation of the data and how does it compare to rivaling treatments?
Added By: slingshot_insights
In “Calm Sea” situations, the Worst MSSS score for patients on tradipitant was higher (3.4) than placebo (3.32). In the “Rough Sea” scenario, tradipitant scored 3.19 and placebo 4.57. What do you attribute those differences to?
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
